Navigation Links
Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
Date:4/8/2013

je una valoración precisa de la plataforma epigenética.

El objetivo de la desincorporación es dividir el programa clínico de RVX-208 (Resverlogix) de la plataforma epigenética (RVX Therapeutics). Así, este proceso creará entornos empresariales diferentes, como el de que Resverlogix está preparado estructuralmente para la adquisición al tiempo que el valor futuro de RVX Therapeutics se conseguirá por medio de un modelo empresarial de licencia y/o asociación.

Esto presenta el potencial para desvelar el valor futuro para RVX Therapeutics por medio de la investigación y desarrollo del mecanismo epigenético, creando un flujo de royalties potenciales desde RVX-208. La mejora del valor de los accionistas a largo plazo se suministra a través de las valoraciones directas relacionadas con cualquier acuerdo de licencia y asociación.

Además, la nueva estructura minimizará las diluciones futuras que la corporación necesite de capital de valores adicional.

Resverlogix seguirá centrándose en el desarrollo clínico de RVX-208, su molécula pequeña para el tratamiento de la ateroesclerosis por medio de los aumentos terapéuticos en Apo A-1. Además, Resverlogix seguirá con su ensayo clínico relacionado con RVX-208 para la diabetes y en breve lanzará el ensayo clínico para la enfermedad de Alzheimer.

RVX Therapeutics se centrará en la investigación y desarrollo relacionado con el innovador fármaco al mejorar la plataforma epigenética en múltiples enfermedades, incluyendo la autoinmune y oncología, excluyendo Apo A-1 y la tecnología RVX-208.

Está previsto que los directores y responsables senior de RVX Therapeutics sigan formando el conjunto de los directores actuales y responsables senior de Resverlogix.

Los accionistas de Resverlogix recibirán una acci
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
2. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
3. Aratana Therapeutics Adds To Drug Development Team
4. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
5. Novira Therapeutics Completes $25 Million Series A Financing
6. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
7. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
8. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
9. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
10. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
11. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
(Date:12/24/2014)... Solutions , Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), today announced that it will hold its ... "Annual Meeting"). Because the expected date for the ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... - Before Congress takes its traditional August break, the ... human embryonic stem cell research. Let's hope a scientifically sound ... as Wisconsin follow the lead. , ,Just as Republicans in ... are GOP leaders in Washington, where President Bush suffered a ...
... Companies that are trying to justify RFID investment wholly ... efficiencies, and shrinkage in their supply chain are merely ... significant opportunities in these areas, it means that gross ... can achieve major improvements even without applying RFID. , ...
... MILWAUKEE - A group of business and technology ... $2.6 million in pledged state funds for the ... collaboration between academic researchers and private industry in southeastern ... Finance Committee by a margin of 15-1, and endorsed ...
Cached Biology Technology:Stem cell debate in Washington grows hotter as summer recess nears 2Stem cell debate in Washington grows hotter as summer recess nears 3The key to finding RFID's ROI 2The key to finding RFID's ROI 3The key to finding RFID's ROI 4Budget axe could cut SE Wisconsin tech alliance funding 2Budget axe could cut SE Wisconsin tech alliance funding 3
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... to their offering. One major trend ... continuous advances in technology, it is important to upgrade ...
(Date:12/10/2014)... been here before: you desperately need to sign into your online ... answer to your secret question. What,s your dog,s birthday? Who was ... , a digital infrastructure security company, launches the app ... with usernames, passwords and PINs – 1U TM . ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... four genes newly associated with severe childhood obesity. They ... in severely obese children. The team found that ... to maintain protein receptors known to be involved in ... for the development of new drugs against obesity. ...
... UNTIL 1 P.M. EDT, APRIL 7, 2013, Cleveland: A compound ... popular energy drinks has been found to promote atherosclerosis ... to Cleveland Clinic research published online this week in the ... that bacteria living in the human digestive tract metabolize the ...
... Kidney stones usually make their presence known suddenly, often ... Each year in the U.S. more than a million ... nephrolithiasis. The total annual cost of treatment exceeds $2.1 ... Information Clearinghouse. Although kidney stone pain may ...
Cached Biology News:Finding genes for childhood obesity 2Cleveland Clinic researchers discover new link between heart disease and red meat 2Cleveland Clinic researchers discover new link between heart disease and red meat 3Flies reveal kidney stones in-the-making 2Flies reveal kidney stones in-the-making 3
S-100 alpha/beta chain (8B10)...
... is a new product number, created ... If showing no availability yet, please ... (Z71,487-9) or contact customer service for ... 100 mm, No. of sidearm 4 ...
... a metabolically stable analog of ... uterine stimulant and abortifacient which ... induce labor. It induces luteolysis ... when given as an intramuscular ...
TGase3 (S-20)...
Biology Products: